Jeeyun Lee1, Seung Tae Kim1, Sungju Park1, Sujin Lee1, Se Hoon Park1, Joon Oh Park1, Ho Yeong Lim1, Hongmo Ahn2, Haesook Bok2, Kyoung-Mee Kim3, Myung Ju Ahn1, Won Ki Kang1, Young Suk Park4. 1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Clinical Trial Center, Samsung Medical Center, Seoul, Korea. 3. Pathology and Translational Genomics, Sungkyunkwan University School of Medicine, Seoul, Korea. 4. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: pys27hmo@skku.edu.
Abstract
BACKGROUND: Samsung Advance Institute of Technology-301 (SAIT301) is a human immunoglobulin G2 antibody that can specifically target mesenchymal epithelial transition factor (c-MET). This novel antibody has higher priority over hepatocyte growth factors when binding to the Sema domain of c-MET and accelerates the internalization and degradation of c-MET, proving its powerful antitumor activities in intra- as well as extracellular areas. MATERIALS AND METHODS: SAIT301 was administered intravenously once every 3 weeks in c-MET overexpressed solid tumor patients, focusing on metastatic colorectal cancer (CRC) according to common clinical phase I criteria. Dose escalation was performed according to a modified Fibonacci design, following the conventional 3+3 design. The purpose of this phase I study was to assess the safety profile, to establish the recommended dose for clinical phase II studies and to assess potential anticancer activity of the compound. RESULTS: Sixteen patients with a median age of 56 (range, 39-69) years were enrolled in the study. The most common adverse events were decreased appetite (50.0%), hypophosphatemia, fatigue and dizziness (25.0%, respectively), and diarrhea, blood alkaline phosphatase increased and dyspnea (18.8%, respectively). For tumor response, no patients achieved complete response. One (9.1%) CRC patient had a partial response in the 1.23 mg/kg group, 4 (36.4%) patients achieved stable disease (2 in the 0.41 mg/kg group, 2 in the 1.23 mg/kg group, 0 in the 3.69 mg/kg group, and 1 in the 8.61 mg/kg group). Because of the increase in dose-limiting toxicities (DLTs) at 8.61 mg/kg, the 3.69 mg/kg dose was considered the maximum tolerated dose and selected for further assessment in phase II. CONCLUSION: We successfully completed a phase I trial with MET antibody in a MET-overexpressed patient population focusing on CRC, and found that the DLTs were alkaline phosphatase elevation or hypophosphatemia. The recommended dose of SAIT301 for phase II is the dose of 3.69 mg/kg.
BACKGROUND: Samsung Advance Institute of Technology-301 (SAIT301) is a human immunoglobulin G2 antibody that can specifically target mesenchymal epithelial transition factor (c-MET). This novel antibody has higher priority over hepatocyte growth factors when binding to the Sema domain of c-MET and accelerates the internalization and degradation of c-MET, proving its powerful antitumor activities in intra- as well as extracellular areas. MATERIALS AND METHODS: SAIT301 was administered intravenously once every 3 weeks in c-MET overexpressed solid tumorpatients, focusing on metastatic colorectal cancer (CRC) according to common clinical phase I criteria. Dose escalation was performed according to a modified Fibonacci design, following the conventional 3+3 design. The purpose of this phase I study was to assess the safety profile, to establish the recommended dose for clinical phase II studies and to assess potential anticancer activity of the compound. RESULTS: Sixteen patients with a median age of 56 (range, 39-69) years were enrolled in the study. The most common adverse events were decreased appetite (50.0%), hypophosphatemia, fatigue and dizziness (25.0%, respectively), and diarrhea, blood alkaline phosphatase increased and dyspnea (18.8%, respectively). For tumor response, no patients achieved complete response. One (9.1%) CRC patient had a partial response in the 1.23 mg/kg group, 4 (36.4%) patients achieved stable disease (2 in the 0.41 mg/kg group, 2 in the 1.23 mg/kg group, 0 in the 3.69 mg/kg group, and 1 in the 8.61 mg/kg group). Because of the increase in dose-limiting toxicities (DLTs) at 8.61 mg/kg, the 3.69 mg/kg dose was considered the maximum tolerated dose and selected for further assessment in phase II. CONCLUSION: We successfully completed a phase I trial with MET antibody in a MET-overexpressed patient population focusing on CRC, and found that the DLTs were alkaline phosphatase elevation or hypophosphatemia. The recommended dose of SAIT301 for phase II is the dose of 3.69 mg/kg.
Authors: Sang-A Kim; Hyejoo Park; Kui-Jin Kim; Ji-Won Kim; Ji Hea Sung; Milang Nam; Ju Hyun Lee; Eun Hee Jung; Koung Jin Suh; Ji Yun Lee; Se Hyun Kim; Jeong-Ok Lee; Jin Won Kim; Yu Jung Kim; Jee Hyun Kim; Soo-Mee Bang; Jong Seok Lee; Keun-Wook Lee Journal: J Cancer Res Clin Oncol Date: 2021-12-01 Impact factor: 4.322
Authors: Edwin Choy; Gregory M Cote; M Dror Michaelson; Lori Wirth; Justin F Gainor; Alona Muzikansky; Lecia V Sequist; Ryan J Sullivan; Panagiotis M Fidias; Alice Shaw; Rebecca S Heist Journal: Oncologist Date: 2022-07-05 Impact factor: 5.837
Authors: Marco Gymnopoulos; Oscar Betancourt; Vincent Blot; Ryo Fujita; Diana Galvan; Vincent Lieuw; Sophie Nguyen; Jeanette Snedden; Christine Stewart; Jose Villicana; Jon Wojciak; Eley Wong; Raul Pardo; Neki Patel; Francois D'Hooge; Balakumar Vijayakrishnan; Conor Barry; John A Hartley; Philip W Howard; Roland Newman; Julia Coronella Journal: Mol Oncol Date: 2019-12-03 Impact factor: 6.603
Authors: Ilaria Martinelli; Chiara Modica; Cristina Chiriaco; Cristina Basilico; James M Hughes; Simona Corso; Silvia Giordano; Paolo M Comoglio; Elisa Vigna Journal: J Exp Clin Cancer Res Date: 2022-03-29